



Health Equity at AstraZeneca

Event for investors and analysts

15 November 2024



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property related risks to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group's financial position; the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's ability to continue to mitigate these risks, and on the Group's operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.





Agenda

I. Sustainability at AstraZeneca

Pam Cheng

II. Our Health Equity Journey

**Dave Fredrickson
and Marc Dunoyer**

III. Our Health Equity Strategy

IV. Equity in Action

V. Q&A Panel

**Health Equity
Leadership Team**



Sustainability at AstraZeneca



Pam Cheng


EXECUTIVE VICE PRESIDENT, GLOBAL
OPERATIONS, INFORMATION TECHNOLOGY
AND CHIEF SUSTAINABILITY OFFICER



Ambition – \$80bn Total Revenue by 2030 & sustained 2030+ growth

Working on “today, tomorrow and the day after”

Illustrative only, not to scale



Note: Ambition to achieve \$80bn in Total Revenue by 2030 is risk-adjusted, based on latest long-range plan – see ‘Forward looking statements’ slide for forward looking statement.


Medicines and assets listed reflect key contributors to 2030 Total Revenue ambition; however, this list is not exhaustive. Medicines and assets listed in alphabetical order and sorted by therapy area.

5

1. NME ambition tracking from date of first regulatory approval, dated from November 2022, total as of November 2024. CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies; ADC = antibody-drug conjugate; RC = radio-conjugate.



Sustainability is core part of achieving our ambitions



Industry-leading efforts in Sustainability

Our three interconnected priorities underpinned by nine focus areas



Progress on our leadership in sustainability includes:

15

public and private sector organisations convened by AstraZeneca CEO through the SMI to accelerate transition to net-zero health systems

87%

of employee survey respondents say that they understand their contributions to our sustainability priorities

25/27

of sustainability targets in Sustainability Data Annex are "on plan"




Driving bold decarbonisation through Ambition Zero Carbon

Scope 1 & 2

		TARGETS:
68%	Reduce Scope 1 & 2 emissions vs. 2015	98% by 2026 ✓
50%	Transition to electric vehicles	100% by 2025 ¹ ✓
103%	Increase energy productivity vs. 2015	200% by 2025 ✓
95%	Increase in renewable electricity consumption vs. 2015	100% from 2025 ✓


Total Revenue vs. Scope 1 & 2 emissions



Scope 3

		TARGETS:
65%	Of suppliers with science-based targets	2025¹ ✓
	Launch next-generation near-zero GWP inhaler	By end of 2025² ✓

Scope 3: strategic emissions approach



Decoupling Total Revenue growth from Scope 1 & 2 emissions reduction

✓ Metric "on plan"

1. By 2025, 95% of our suppliers by spend covering purchased goods and services and capital goods, and 50% of our suppliers by spend covering upstream transportation and distribution and business travel, will have SBTs.

8 2. Timelines subject to regulatory review and approval processes

tCO2e = tonnes of carbon dioxide equivalent; SBTi = Science Based Targets Initiative; GWP = Global Warming Potential.



Building more sustainable and resilient healthcare systems across the world

Partnership for Health System Sustainability and Resilience (PHSSR)

Co-founded by:



Key ongoing initiatives



Sustainable Markets Initiative

Partnering to drive focused interventions, policy change and scalable action




Acting now to secure a sustainable future for *all*

Climate action



The climate crisis is worsening the burden of disease

Resilience



Health systems are unable to cope with rising demands

Health equity



Health disparities are widening within and between countries



Health Equity at AstraZeneca




Dave Fredrickson
EXECUTIVE VICE PRESIDENT,
ONCOLOGY BUSINESS



Our journey to date: A foundation of successful philanthropic programmes

2010 – TODAY



66.4m people
reached through
philanthropic programs¹
surpassing target of
50m by 2025




>127,300
healthcare workers
trained² on-plan to
achieve target
of 170,000 by 2025



Our journey to date: Expanding access via strategic adjacencies across our therapeutic areas

2010 – TODAY



The Lung Ambition Alliance

Ambition to eliminate lung cancer as a cause of death

COVID-19 Response



>6.5 million lives saved through not-for-profit vaccine¹

Expansion into Rare Disease

Reaching >70 countries with rare disease treatments






Care gaps exist at every step of the patient journey



Determinants of health outcomes amplify these care gaps globally

Determinants of health outcomes



Broadening “Access to Healthcare” to “Health Equity” at AstraZeneca

The journey to our Health Equity strategy



Evaluate

current and future
health equity initiatives

>170

existing health equity-related
initiatives across our organisation

>40

additional high-impact ideas and
initiatives identified



Engage

key stakeholders
to enable change

Conducted interviews
and workshops with
stakeholders across
health ecosystem




Action

high-impact
opportunities




Embedding health
equity across our
global organisation
via market-tailored
framework



Our vision is to drive health equity across all healthcare systems and income segments

Equity focus across income segments



Our vision:

Working to remove barriers to healthcare to give **everyone** the chance to be **as healthy as possible**

Our impact:

Introducing KPIs in 2025 to measure our impact



Our Health Equity strategy underpinning our ambition

Our strategy:

To achieve holistic impact across three key focus areas

SCIENCE

Ensure more individuals **can equitably benefit** from our trials, science and capabilities

DELIVERY

Improve **equitable health outcomes** focus on early detection, precision diagnosis and guideline-concordant treatment

CAPABILITIES & ENGAGEMENT

Amplify health equity impact by building trust with partners and purpose with employees



Leading in discovery diversity with our genomics initiative

SCIENCE

Discovery diversity

Inclusive R&D

Building an extensive 'omics database since 2017

1.4m

exomes/genomes sequenced


>280

from clinical trials across all therapeutic areas

55+

external academic/biobank collaborations

Our 'omics diversity progress



Next steps



Driving greater diversity in 'omics



Leverage AI to identify target-disease relationships



Understand gaps to shape our R&D strategy



Committed to enrolling diverse clinical trial populations to improve equitable access


SCIENCE

Discovery diversity

Inclusive R&D

Progress to date

CTD Dashboard
with real-time recruitment tracking for all Phase III US trials¹



Monitoring age, sex, race and ethnicity

Establishing collaborations
to co-develop solutions



Next steps



Ensure clinical trial populations represent real-world disease demographics



Develop, understand and shape the external landscape



Expand collaborations and partnerships ex-US

Underpinned by AZ standard to guide our R&D principles



We remain committed to our philanthropic efforts: growing impact from Young Health Programme

DELIVERY

Health awareness
and education

Closing care gaps


Affordability and
accessibility

AstraZeneca Young Health Programme

>15 million
young people
directly reached

>800,000
people trained

>16,000
employee
volunteers



16 high income
countries

**18 upper
middle-income**
countries

**7 lower
middle-income**
countries

Active in **>40 countries worldwide** with ambition for continued expansion



We remain committed to our philanthropic efforts: Health Heart Africa expanding into CKD

DELIVERY

Health awareness
and education

Closing care gaps

Affordability and
accessibility

AstraZeneca
Healthy Heart Africa
*tackling hypertension and
the burden of cardiovascular
disease across Africa*



**Achieved target
with >10m people**
identified with elevated
blood pressure readings




**Expansion
into CKD ongoing,**
driving further impact
across Africa

Progress to-date:

>11,400 healthcare
workers trained

>1,500 healthcare
facilities
activated

>61m blood pressure
screenings
conducted¹







Partnering along the entire patient journey to close care gaps and improve equitable outcomes

DELIVERY

Awareness and education

Closing care gaps

Affordability and accessibility



Partnering along the entire patient journey to close care gaps and improve equitable outcomes

DELIVERY

Awareness and education

Closing care gaps

Affordability and accessibility



Early detection




Only 18%
of eligible people access lung cancer screening¹



Precision diagnosis




c.4.3 years
to definitive diagnosis for rare disease patients²



Guideline-based care



Only 2.8%
of diabetic CKD patients take an SGLT2 inhibitor³



Treatment adherence and disease monitoring



c.41%
of cancer patients travel >100km for treatment⁴




Our four principles to sustainable affordability

Multiple factors influence affordability and accessibility



Affordability and accessibility varies by market



Capabilities and engagement

Building trust with partners and purpose with employees

CAPABILITIES & ENGAGEMENT

Partnerships and stakeholder engagement


Culture and employee engagement

Health Equity science and analytics

AstraZeneca Health Equity Advisory Board

established in 2024

11 countries across 5 continents represented



Introducing Health Equity KPIs to Scorecard in 2025



Engaging employees to build culture on integrated Health Equity strategies



Equity in Action across AstraZeneca



Dave Fredrickson

EXECUTIVE VICE PRESIDENT,
ONCOLOGY BUSINESS




Marc Dunoyer

CHIEF EXECUTIVE OFFICER,
ALEXION AND CHIEF STRATEGY
OFFICER, ASTRAZENECA



Lung health is a key priority for AstraZeneca




29% of lung cancer deaths associated with air pollution⁵ | c.75% of COPD GHG emissions associated with hospital care⁶




Lung health outcomes are influenced by similar barriers across the patient journey


Determinants of health outcomes



Who is impacted?




What access barriers do they face?



Understanding care gaps with precision analytics to maximise our impact in lung health

Who faces care gaps?



Identify and execute on actionable drivers of disparities:



Areas with low lung cancer incidence and higher mortality rates to inform **stage shift strategy in hotspot areas of inequity**



Regions with **high incidence COPD, underdiagnosis and not receiving standard-of-care** due to inequities



How our clinical trial sites map against **areas of highest relative inequity** and **where populations underserved by clinical trials are located**



Driving early detection of disease through lung screening programs



AI-powered diagnostic partnership

leveraging chest x-rays globally

- 17% improvement in detecting lung nodules¹
- Applicable to LMICs

quire.ai

On track to screen
5 million
patients by 2025

UK lung cancer screening programme

driving more lung cancer diagnoses in deprived groups²

- Drove initial awareness campaign
- Supported evidence generation and economic modelling
- Advocated for policy change

NHS




Targeted Lung
Health Check
Programme

Opportunity for a collaborative approach for the detection of lung diseases



Breathlessness is a common symptom across diseases; delayed diagnosis associated with worse outcomes



Accelerating diagnosis of heart failure and COPD through community-based screening

Leveraging AI to accelerate detection of Heart Failure

- Validated AI-assisted ultrasound testing outside of hospital setting¹
- Reduced waiting time from 12 months to <6 weeks in Scotland
- Ongoing SYMPHONY trial to expand application in 5 countries


Partnering with:



Innovative Community outreach through sports club

- Heart and lung screening hub in one of the UK's most deprived areas
- Building trust with hard-to-reach patient group
- >1,000 screened driving new HF, hypertension and COPD diagnoses

Partnering with:



Improving cardiac amyloidosis diagnosis through innovative AI partnerships

Amyloidosis patient journey


> Presents with symptoms

> Initial work-up and echo

> Diagnosis

> Treatment and follow-up

Enhancing detection of amyloidosis signatures via AI software



Echocardiogram is a key early exam, yet there is low detection of amyloidosis due to manual processing

Accelerating amyloidosis disease detection to drive earlier intervention and improve patient outcomes

Partnering with:



Validating in community setting to demonstrate earlier patient identification outside of hospital care

✓ FDA Clearance



Developing AI software medical device to analyse echocardiogram videos

✓ FDA BT¹



Amyloidosis is a strategic priority across CVRM and Rare Disease

A portfolio to address the two most prevalent cardiac amyloidosis

Transthyretin (ATTR) amyloidosis

Light-chain (AL) amyloidosis

Complimentary mechanisms

Wainua

Silencer blocks TTR synthesis

ALXN2220

Depleter binds to misfolded TTR, removes toxic fibrils

~114k diagnosed
in US and EU5



anselamimab

Depleter selectively binds to light chain fibrils

~28k diagnosed
in US and EU5



Being born with a rare disease is inherently inequitable

1 in 10

people live with a rare disease¹

10,000

known rare diseases
>90% do not have an approved treatment^{2,3}

5+ years

and >7 specialists to reach rare disease diagnosis⁴

80%


of rare diseases are genetic¹

6-10x higher

economic burden of rare diseases vs. non-rare diseases⁵



Patients with rare disease face multiple inequities across the diagnosis and treatment pathway



Sparse or limited data



Limited access



Limited knowledge and understanding



Long and complex diagnostic pathway



Poor access and quality of clinical care



Disproportionate impact on health system ecosystems



Newborn screening, one of the most successful public health programmes but only covers a small fraction of diseases today

Current newborn screening progress

40m newborns
screened worldwide per year¹

>80 countries
with screening programs²

>12,500 screened
and diagnosed in the US per year²

Challenges

— Screening covers too few diseases:



37
diseases³



9
diseases⁴



5
diseases⁵

— No screening available for many rare diseases

— Long lead times for including additional diseases into screening

Next steps for next-generation sequencing for:

> all babies admitted to the NICU

or

> all newborns

>5,000 gene therapy trials listed with NIH⁶



Establishing newborn screening as standard-of-care as part of 'BeginNGS' genome sequencing consortium


80% of rare diseases are genetic²

BeginNGS[®]

Consortium focused on expanding newborn screening in rare diseases¹ to:

- Identify patients earlier
- Increase clinical trial enrollment
- Accelerate treatment to improve outcomes

Progress to date:



BeginNGS ambition

aligned with our genomic medicine strategy

screen >1m newborns for >700 genetic conditions¹



Driving health equity while delivering shareholder value

2030 Ambition



To deliver **\$80bn in Total Revenue** by 2030, with sustained growth 2030+



- **Mid-30s% Core operating margin** by 2026
- Beyond 2026, Core operating margin will be influenced by portfolio evolution and the Company will target **at least mid-30s%**

Health Equity Ambition

Our vision:

working to remove barriers to healthcare to give **everyone** the chance to be **as healthy as possible**

Our impact:

introducing KPIs in 2025 to measure our impact



Q&A Session

with Key Health Equity Leaders



Pam Cheng

EXECUTIVE VICE PRESIDENT, GLOBAL OPERATIONS, INFORMATION TECHNOLOGY AND CHIEF SUSTAINABILITY OFFICER



Stefan Weber

VICE PRESIDENT, POLICY, PATIENT ADVOCACY AND HEALTH EQUITY



Dave Fredrickson

EXECUTIVE VICE PRESIDENT, ONCOLOGY BUSINESS



Elena Tricca

VICE PRESIDENT, GLOBAL MARKET ACCESS AND PRICING, BIOPHARMACEUTICALS



Marc Dunoyer

CHIEF EXECUTIVE OFFICER, ALEXION AND CHIEF STRATEGY OFFICER, ASTRAZENECA



Sustainability Governance at AstraZeneca

Board of Directors – Delegated Committees

Board Audit Committee



Philip Broadley

*Senior Independent Non-Executive Director of the Board,
Chair of the Audit Committee*



Sheri McCoy

Non-Executive Director of the Board



Deborah DiSanzo

Non-Executive Director of the Board



Anna Manz

Non-Executive Director of the Board

Sustainability Committee



Nazneen Rahman

*Non-Executive Director of the Board,
Chair of the Sustainability Committee*



Sheri McCoy

Non-Executive Director of the Board



Marcus Wallenberg

Non-Executive Director of the Board



Andreas Rummelt

Non-Executive Director of the Board

Remuneration Committee



Sheri McCoy

*Non-Executive Director of the Board,
Chair of the Remuneration Committee*



Nazneen Rahman

Non-Executive Director of the Board



Philip Broadley

Senior Independent Non-Executive Director of the Board

Senior Executive Team (SET)



Pascal Soriot

Executive Director and Chief Executive Officer



Pam Cheng

*Executive Vice President, Global Operations,
Information Technology and Chief Sustainability Officer*



Jeff Pott

*Chief Human Resources Officer, Chief Compliance Officer
and General Counsel*

Sustainability Steering Committee

Sustainability

Compliance

Procurement

Communications

Legal

Finance

Human Resources

Supply Chain

Health Equity



Use of AstraZeneca slides from conference calls and webcasts

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

